
    
      This is a prospective, single arm, multi-centre, post-market study to further assess safety
      and efficacy in 20 unresectable HCC patients treated with Doxorubicin loaded BioPearlâ„¢
      microspheres.

      After the treatment procedure, all patients will undergo clinical follow-up until disease
      progression and/or next treatment option after which patients will be followed for survival.
      Patients will be followed up to a maximum of 3 years.
    
  